Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034
Description
Nuclear Medicine (Radiopharmaceuticals) Market Summary
This nuclear medicine (radiopharmaceuticals) market report offers a comprehensive overview of the global nuclear medicine (radiopharmaceuticals) market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-125, Xenon-133, and Others} and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], and Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]), Application (Cardiology, Neurology, Oncology, and Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing nuclear medicine (radiopharmaceuticals) market.
Nuclear medicine and radiopharmaceuticals refer to a specialized field of medical imaging and therapy that uses small amounts of radioactive substances (radiopharmaceuticals) to diagnose and treat various diseases. These radioactive compounds are introduced into the body, where they accumulate in specific organs or tissues and emit radiation that can be detected using imaging systems such as PET or SPECT scanners. This enables physicians to visualize organ function, detect abnormalities at an early stage, and monitor disease progression. In addition to diagnosis, certain radiopharmaceuticals are also used in targeted treatments, particularly for conditions such as cancer, thyroid disorders, and some neurological diseases.
The nuclear medicine (radiopharmaceuticals) market is witnessing substantial growth due to several key factors. One of the major drivers is the increasing prevalence of chronic diseases, including cancer and cardiovascular diseases, which has increased the need for advanced diagnostic and therapeutic solutions. In addition, the rising demand for targeted radiotherapy is supporting market expansion, as radiopharmaceuticals enable precise delivery of radiation to diseased cells while minimizing damage to surrounding healthy tissues. Furthermore, the growing adoption of advanced imaging technologies, such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), is enhancing disease detection and monitoring by providing detailed functional imaging. These factors collectively contribute to the increasing utilization of nuclear medicine procedures, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.
Get More Insights into the Report @Nuclear Medicine (Radiopharmaceuticals) Market
What are the latest nuclear medicine (radiopharmaceuticals) market dynamics and trends?
The nuclear medicine (radiopharmaceuticals) market is witnessing strong growth driven by the rising prevalence of cancer and cardiovascular diseases, increasing demand for targeted radiotherapy, and the expanding use of advanced imaging technologies such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT).
According to the Institute for Health Metrics and Evaluation (2025), there were 437 million cardiovascular disease (CVD) disability-adjusted life years (DALYs) globally in 2023.
Cardiovascular diseases (CVDs), being a leading cause of morbidity and mortality globally, have significantly increased the demand for precise diagnosis, risk evaluation, and treatment monitoring. Nuclear medicine imaging techniques, such as myocardial perfusion imaging performed using PET and SPECT scans, enable physicians to evaluate blood flow to the heart, detect coronary artery blockages, assess heart muscle function, and identify areas with reduced oxygen supply. Radiopharmaceuticals, including technetium-99m-based tracers and other cardiac imaging agents, are widely used to diagnose conditions such as coronary artery disease, myocardial ischemia, and heart failure, thereby contributing significantly to the growth of the nuclear medicine (radiopharmaceuticals) market.
Moreover, according to the International Agency for Research on Cancer (2026), the estimated number of new thyroid cancer cases globally was 863,000 in 2025 and is projected to reach 1.07 million by 2045. As per the same source, the estimated number of new cases of prostate cancer was 1.57 million in 2025 and is projected to increase to 2.63 million by 2045. These cancers often require advanced nuclear imaging and targeted radiotherapy for accurate diagnosis, staging, and treatment monitoring. In thyroid cancer, radiopharmaceuticals such as radioactive iodine are widely used for both diagnostic imaging and targeted treatment of cancerous thyroid tissue. Similarly, in prostate cancer, imaging techniques like positron emission tomography (PET) using prostate-specific tracers help detect tumor spread and support effective treatment planning, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.
However, the increase in product development activities is further boosting the overall market of nuclear medicine/ radiopharmaceuticals. For instance, in March 2025, Telix Pharmaceuticals Limited announced that the United States Food and Drug Administration (FDA) had approved its New Drug Application (NDA) for Gozellix® (TLX007‑CDx, a kit for the preparation of gallium‑68 [⁶⁸Ga] gozetotide injection), Telix’s next‑generation PSMA‑PET imaging agent for prostate cancer.
Thus, the factors mentioned above are expected to boost the overall market of nuclear medicine (radiopharmaceuticals) during the forecast period from 2026 to 2034.
However, the growth of nuclear medicine (radiopharmaceuticals) is restrained by several challenges, including the short half-life of many radioisotopes, which makes storage and transportation difficult and requires production facilities to be located near healthcare centers. In addition, the high cost of specialized infrastructure, such as cyclotrons, PET/SPECT scanners, and radiation-shielded facilities, limits adoption in many hospitals. Strict regulatory and radiation safety requirements further complicate the manufacturing, handling, and approval of radiopharmaceuticals. Moreover, concerns about radiation exposure, limited availability of skilled professionals, and occasional supply shortages of medical isotopes also restrict the wider use of nuclear medicine technologies in clinical practice.
Nuclear Medicine (Radiopharmaceuticals) Market Segment Analysis
Nuclear Medicine (Radiopharmaceuticals) Market by Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-125, Xenon-133, and Others} and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], and Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]), Application (Cardiology, Neurology, Oncology, and Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
Nuclear Medicine (Radiopharmaceuticals) Market Regional Analysis
North America Nuclear Medicine (Radiopharmaceuticals) Market Trends
North America is expected to account for the highest proportion of 42% of the nuclear medicine (radiopharmaceuticals) market in 2025, out of all regions. This dominance is driven by the rising prevalence of cancer, cardiovascular, and other chronic diseases linked to lifestyle changes and high processed food consumption. Additionally, the presence of major local players and a growing geriatric population susceptible to chronic conditions further strengthens the market in the region.
According to the Centers for Disease Control and Prevention, in 2024, approximately 805,000 people in the United States experienced a heart attack. As per the same source, it was estimated that approximately 12.1 million people in the United States would have atrial fibrillation (AFib) by 2050. These cardiovascular conditions demand accurate diagnosis, risk evaluation, and ongoing monitoring of heart function, where nuclear imaging techniques such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and myocardial perfusion scans play a vital role. Radiopharmaceuticals, integral to these imaging procedures, enable non-invasive detection of damaged heart tissue, assessment of blood flow, and evaluation of arrhythmias. This increasing reliance on advanced cardiac imaging is driving the growth of the nuclear medicine (radiopharmaceuticals) market.
Moreover, according to a 2022 study led by the Parkinson’s Foundation, nearly 90,000 people were diagnosed with Parkinson’s disease each year in the United States. The study also estimates that by 2030, approximately 1.2 million people in the U.S. will be living with Parkinson’s disease. Nuclear imaging techniques such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) play a key role in detecting dopamine transporter activity and assessing brain function. Radiopharmaceuticals used in these scans allow clinicians to visualize neuronal loss and monitor disease progression non-invasively. As the number of Parkinson’s patients increases globally, demand for these advanced diagnostic tools rises, thereby driving growth in the nuclear medicine (radiopharmaceuticals) market.
However, the increase in product development activities is further boosting the overall market of Nuclear medicine/ radiopharmeceuticals. For instance, in April 2024, Novartis’ radioligand therapy Lutathera® was approved by the FDA as the first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors.
Thus, all the above-mentioned factors are anticipated to propel the market for nuclear medicine (radiopharmaceuticals) in North America during the forecast period.
Europe Nuclear Medicine (Radiopharmaceuticals) Market Trends
The nuclear medicine (radiopharmaceuticals) market in Europe is growing due to the rising prevalence of cancer, cardiovascular diseases, and neurodegenerative disorders, increasing demand for early diagnosis, and the adoption of advanced imaging technologies like PET and SPECT for accurate, non-invasive disease detection and monitoring.
According to the Organisation for Economic Co-operation and Development, in 2022, cardiovascular diseases affected an estimated 62 million people in Europe. Accurate diagnosis and monitoring of heart conditions, including heart attacks, coronary artery disease, and arrhythmias, rely on advanced imaging techniques such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and myocardial perfusion scans. Radiopharmaceuticals play a crucial role in these procedures by enabling non-invasive assessment of blood flow, detection of damaged heart tissue, and evaluation of cardiac function, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.
Additionally, according to the International Agency for Research on Cancer, the estimated number of new Liver Cancer cases in Europe was 78,600 in 2025, and it is projected to reach 75,500 by 2045. The diagnosis, staging, and treatment of Thyroid Cancer heavily depend on nuclear imaging techniques such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography), along with radioisotope-based therapies like radioactive iodine. Radiopharmaceuticals are essential for detecting malignant thyroid tissue, monitoring metastasis, and delivering targeted therapy, allowing for precise and non-invasive disease management. This growing reliance on nuclear medicine is driving the expansion of the radiopharmaceuticals market.
However, the increase in product development activities is further boosting the overall market of nuclear medicine/ radiopharmaceuticals. For instance, in November 2024, Eckert & Ziegler Radiopharma GmbH received approval from the European Commission for its proprietary non-carrier-added Lutetium-177 chloride, Theralugand®.
Hence, all the factors mentioned above are expected to drive the market for nuclear medicine (radiopharmaceuticals) in Europe during the forecast period.
Asia-Pacific Nuclear Medicine (Radiopharmaceuticals) Market Trends
The nuclear medicine (radiopharmaceuticals) market in the Asia-Pacific region is expanding, driven by the increasing incidence of cancer, cardiovascular, and neurodegenerative disorders, rising healthcare spending, enhanced diagnostic infrastructure, and wider adoption of advanced imaging techniques and radiopharmaceutical treatments.
According to the International Agency for Research on Cancer, the estimated number of new thyroid cancer cases in Japan was 16,400 in 2025 and is projected to reach 15,100 by 2045. Thyroid cancer diagnosis and treatment rely on nuclear imaging techniques like PET and SPECT, along with radioisotope therapies such as radioactive iodine. Radiopharmaceuticals help detect malignant tissue, monitor metastasis, and deliver targeted therapy, driving growth in the nuclear medicine (radiopharmaceuticals) market.
Thus, the factors mentioned above are expected to boost the market of nuclear medicine (radiopharmaceuticals) across the Asia-Pacific region.
Who are the major players in the nuclear medicine (radiopharmaceuticals) market?
The following are the leading companies in the nuclear medicine (radiopharmaceuticals) market. These companies collectively hold the largest market share and dictate industry trends.
The competitive landscape of the nuclear medicine (radiopharmaceuticals) market is shaped by the presence of several global and regional key players competing through product innovation, strategic collaborations, and geographic expansion. Leading companies such as GE Healthcare, Bayer AG, Novartis/Advanced Accelerator Applications, Jubilant Life Sciences, and Curium Pharma are heavily investing in research and development to introduce new radiopharmaceuticals for both diagnostic and therapeutic applications. Additionally, mergers, acquisitions, and partnerships are enabling companies to expand their product portfolios, enhance distribution networks, and access new markets, particularly in emerging regions. Moreover, regulatory approvals for novel radiotracers and continuous advancements in imaging technologies like PET, SPECT, and theranostics are driving innovation and competitive differentiation. Smaller specialized firms are also entering the market with niche radiopharmaceuticals, increasing market fragmentation and innovation.
Consequently, the competitive environment is fostering rapid technological advancements, expanded product offerings, and improved accessibility, which together are shaping the growth trajectory of the global nuclear medicine (radiopharmaceuticals) market.
Recent Developmental Activities in the Nuclear Medicine (Radiopharmaceuticals) Market
Neurology
Oncology
Others
Diagnostic Centers
Others
AI-Powered Innovations and Applications:
The adoption of AI-powered innovations is significantly transforming the nuclear medicine (radiopharmaceuticals) market by enhancing both diagnostic accuracy and operational efficiency. AI algorithms are being integrated into imaging systems, such as PET and SPECT scanners, to improve image reconstruction, reduce noise, and detect abnormalities with higher precision, allowing clinicians to identify diseases at earlier stages. Additionally, AI facilitates automated workflow management, including patient scheduling, radiopharmaceutical dose calculation, and quality control, reducing human error and optimizing resource utilization. Moreover, AI applications in theranostics are enabling personalized treatment planning by analyzing large datasets to predict patient response to radiopharmaceutical therapies, such as targeted cancer treatments. The integration of AI also supports drug development, helping manufacturers design more effective radiotracers and accelerate regulatory approvals. Consequently, AI-driven innovations are improving clinical outcomes, reducing operational costs, and increasing the adoption of nuclear medicine procedures, thereby boosting the overall growth and efficiency of the nuclear medicine (radiopharmaceuticals) market.
U.S. Tariff Impact Analysis on Nuclear Medicine (Radiopharmaceuticals) Market:
The U.S. tariffs on imported medical equipment and radiopharmaceuticals have had a notable impact on the nuclear medicine (radiopharmaceuticals) market. Increased import duties on raw materials, isotopes, and diagnostic kits have raised the cost of production for domestic manufacturers relying on global supply chains. Additionally, higher costs are often passed on to healthcare providers, potentially limiting the adoption of advanced nuclear imaging and therapeutic procedures in cost-sensitive hospitals and clinics. Moreover, tariffs may prompt companies to invest in local manufacturing and supply chain diversification to reduce dependency on imports, which could increase initial capital expenditures but improve long-term market stability. Consequently, while tariffs may temporarily slow market growth due to higher prices, they also encourage strategic localization and innovation, shaping the competitive and operational landscape of the U.S. nuclear medicine (radiopharmaceuticals) market.
How This Analysis Helps Clients
1. What is the growth rate of the nuclear medicine (radiopharmaceuticals) market?
- The global nuclear medicine (radiopharmaceuticals) market is expected to increase from USD 10,746.92 million in 2025 to USD 24,152.35 million by 2034, reflecting strong and sustained growth.
- The global nuclear medicine (radiopharmaceuticals) market is growing at a CAGR of 9.50% during the forecast period from 2026 to 2034.
- The nuclear medicine (radiopharmaceuticals) market is primarily driven by the growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which increases the demand for advanced diagnostic and therapeutic solutions. Additionally, technological advancements in imaging systems, radiotracer development, and theranostics have improved accuracy, safety, and patient outcomes. Moreover, expanding healthcare infrastructure, rising awareness about early disease detection, and favorable government initiatives consistently support the adoption of nuclear medicine procedures. Consequently, these factors collectively fuel the growth of the global nuclear medicine (radiopharmaceuticals) market.
- The leading companies operating in the nuclear medicine (radiopharmaceuticals) market include Lantheus, Cardinal Health, GE Healthcare, Curium Pharma,Pharmalogic Holdings Corp., Novartis, Cambridge Isotope Laboatories, Inc., Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, NECSA Ltd., IBA Radiopharma Solutions, Bayer AG, Norgine, NorthStar Medical Radioisotopes, LLC, Eckert & Ziegler, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, ROTOP Pharmaka GmbH and others.
- North America is expected to remain a leading region in the global nuclear medicine (radiopharmaceuticals) market due to a high prevalence of chronic diseases such as cancer and heart conditions, which drives demand for advanced diagnostic and therapeutic solutions. Additionally, the region has well-developed healthcare infrastructure and access to cutting-edge imaging technologies like PET and SPECT scanners. Moreover, supportive government policies, strong research and development activities, and increasing public awareness about early disease detection consistently boost the adoption of nuclear medicine procedures, making North America the largest market globally.
- In the product type segment of the nuclear medicine (radiopharmaceuticals) market, within diagnostic products segment, the iodine-125 category under single photon emission computed tomography (SPECT) is estimated to account for the largest market share in 2025.
- Rising prevalence of cancer, cardiovascular and other chronic diseases: The rising prevalence of cancer, cardiovascular, and other chronic diseases is a key driver for the nuclear medicine (radiopharmaceuticals) market. As the number of patients with conditions such as oncological, cardiac, and neurological disorders increases, the demand for advanced diagnostic and therapeutic solutions grows. Nuclear medicine enables early and accurate detection, functional imaging of organs, and targeted treatment, which is critical for effective disease management. Consequently, the increasing burden of chronic diseases directly boosts the adoption of nuclear medicine procedures and radiopharmaceuticals, supporting the market’s steady growth.
- Increasing demand for targeted radiotherapy : The increasing demand for targeted radiotherapy is a key driver of the nuclear medicine (radiopharmaceuticals) market. Targeted radiotherapy, also known as radioligand therapy, involves delivering radioactive compounds directly to cancerous cells, minimizing damage to healthy tissues and improving treatment precision. This approach is particularly effective for conditions such as neuroendocrine tumors, prostate cancer, and certain types of thyroid and liver cancers, where conventional therapies may be less effective or cause significant side effects. The growing adoption of targeted radiotherapy is fueled by advancements in radiopharmaceutical development, improved imaging techniques, and increasing awareness among clinicians and patients about its efficacy and safety. As more hospitals and specialized cancer centers integrate these therapies into their treatment protocols, the demand for radiopharmaceuticals continues to rise, driving significant growth in the global nuclear medicine market.
- Growing adoption of PET and SPECT Imaging : The growing adoption of PET and SPECT imaging is a major driver of the nuclear medicine (radiopharmaceuticals) market. Advanced imaging technologies such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are widely used for the early detection, diagnosis, and monitoring of various diseases, including cancer, cardiovascular disorders, and neurological conditions. These imaging techniques rely on specialized radiopharmaceuticals to visualize metabolic and physiological processes within the body with high precision. Their ability to provide accurate, non-invasive, and functional imaging has increased their adoption in hospitals and diagnostic centers. As the demand for early and precise diagnosis continues to rise, the use of PET and SPECT imaging is expanding, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.
This nuclear medicine (radiopharmaceuticals) market report offers a comprehensive overview of the global nuclear medicine (radiopharmaceuticals) market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-125, Xenon-133, and Others} and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], and Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]), Application (Cardiology, Neurology, Oncology, and Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing nuclear medicine (radiopharmaceuticals) market.
Nuclear medicine and radiopharmaceuticals refer to a specialized field of medical imaging and therapy that uses small amounts of radioactive substances (radiopharmaceuticals) to diagnose and treat various diseases. These radioactive compounds are introduced into the body, where they accumulate in specific organs or tissues and emit radiation that can be detected using imaging systems such as PET or SPECT scanners. This enables physicians to visualize organ function, detect abnormalities at an early stage, and monitor disease progression. In addition to diagnosis, certain radiopharmaceuticals are also used in targeted treatments, particularly for conditions such as cancer, thyroid disorders, and some neurological diseases.
The nuclear medicine (radiopharmaceuticals) market is witnessing substantial growth due to several key factors. One of the major drivers is the increasing prevalence of chronic diseases, including cancer and cardiovascular diseases, which has increased the need for advanced diagnostic and therapeutic solutions. In addition, the rising demand for targeted radiotherapy is supporting market expansion, as radiopharmaceuticals enable precise delivery of radiation to diseased cells while minimizing damage to surrounding healthy tissues. Furthermore, the growing adoption of advanced imaging technologies, such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), is enhancing disease detection and monitoring by providing detailed functional imaging. These factors collectively contribute to the increasing utilization of nuclear medicine procedures, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.
Get More Insights into the Report @Nuclear Medicine (Radiopharmaceuticals) Market
What are the latest nuclear medicine (radiopharmaceuticals) market dynamics and trends?
The nuclear medicine (radiopharmaceuticals) market is witnessing strong growth driven by the rising prevalence of cancer and cardiovascular diseases, increasing demand for targeted radiotherapy, and the expanding use of advanced imaging technologies such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT).
According to the Institute for Health Metrics and Evaluation (2025), there were 437 million cardiovascular disease (CVD) disability-adjusted life years (DALYs) globally in 2023.
Cardiovascular diseases (CVDs), being a leading cause of morbidity and mortality globally, have significantly increased the demand for precise diagnosis, risk evaluation, and treatment monitoring. Nuclear medicine imaging techniques, such as myocardial perfusion imaging performed using PET and SPECT scans, enable physicians to evaluate blood flow to the heart, detect coronary artery blockages, assess heart muscle function, and identify areas with reduced oxygen supply. Radiopharmaceuticals, including technetium-99m-based tracers and other cardiac imaging agents, are widely used to diagnose conditions such as coronary artery disease, myocardial ischemia, and heart failure, thereby contributing significantly to the growth of the nuclear medicine (radiopharmaceuticals) market.
Moreover, according to the International Agency for Research on Cancer (2026), the estimated number of new thyroid cancer cases globally was 863,000 in 2025 and is projected to reach 1.07 million by 2045. As per the same source, the estimated number of new cases of prostate cancer was 1.57 million in 2025 and is projected to increase to 2.63 million by 2045. These cancers often require advanced nuclear imaging and targeted radiotherapy for accurate diagnosis, staging, and treatment monitoring. In thyroid cancer, radiopharmaceuticals such as radioactive iodine are widely used for both diagnostic imaging and targeted treatment of cancerous thyroid tissue. Similarly, in prostate cancer, imaging techniques like positron emission tomography (PET) using prostate-specific tracers help detect tumor spread and support effective treatment planning, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.
However, the increase in product development activities is further boosting the overall market of nuclear medicine/ radiopharmaceuticals. For instance, in March 2025, Telix Pharmaceuticals Limited announced that the United States Food and Drug Administration (FDA) had approved its New Drug Application (NDA) for Gozellix® (TLX007‑CDx, a kit for the preparation of gallium‑68 [⁶⁸Ga] gozetotide injection), Telix’s next‑generation PSMA‑PET imaging agent for prostate cancer.
Thus, the factors mentioned above are expected to boost the overall market of nuclear medicine (radiopharmaceuticals) during the forecast period from 2026 to 2034.
However, the growth of nuclear medicine (radiopharmaceuticals) is restrained by several challenges, including the short half-life of many radioisotopes, which makes storage and transportation difficult and requires production facilities to be located near healthcare centers. In addition, the high cost of specialized infrastructure, such as cyclotrons, PET/SPECT scanners, and radiation-shielded facilities, limits adoption in many hospitals. Strict regulatory and radiation safety requirements further complicate the manufacturing, handling, and approval of radiopharmaceuticals. Moreover, concerns about radiation exposure, limited availability of skilled professionals, and occasional supply shortages of medical isotopes also restrict the wider use of nuclear medicine technologies in clinical practice.
Nuclear Medicine (Radiopharmaceuticals) Market Segment Analysis
Nuclear Medicine (Radiopharmaceuticals) Market by Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-125, Xenon-133, and Others} and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], and Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]), Application (Cardiology, Neurology, Oncology, and Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
Nuclear Medicine (Radiopharmaceuticals) Market Regional Analysis
North America Nuclear Medicine (Radiopharmaceuticals) Market Trends
North America is expected to account for the highest proportion of 42% of the nuclear medicine (radiopharmaceuticals) market in 2025, out of all regions. This dominance is driven by the rising prevalence of cancer, cardiovascular, and other chronic diseases linked to lifestyle changes and high processed food consumption. Additionally, the presence of major local players and a growing geriatric population susceptible to chronic conditions further strengthens the market in the region.
According to the Centers for Disease Control and Prevention, in 2024, approximately 805,000 people in the United States experienced a heart attack. As per the same source, it was estimated that approximately 12.1 million people in the United States would have atrial fibrillation (AFib) by 2050. These cardiovascular conditions demand accurate diagnosis, risk evaluation, and ongoing monitoring of heart function, where nuclear imaging techniques such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and myocardial perfusion scans play a vital role. Radiopharmaceuticals, integral to these imaging procedures, enable non-invasive detection of damaged heart tissue, assessment of blood flow, and evaluation of arrhythmias. This increasing reliance on advanced cardiac imaging is driving the growth of the nuclear medicine (radiopharmaceuticals) market.
Moreover, according to a 2022 study led by the Parkinson’s Foundation, nearly 90,000 people were diagnosed with Parkinson’s disease each year in the United States. The study also estimates that by 2030, approximately 1.2 million people in the U.S. will be living with Parkinson’s disease. Nuclear imaging techniques such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) play a key role in detecting dopamine transporter activity and assessing brain function. Radiopharmaceuticals used in these scans allow clinicians to visualize neuronal loss and monitor disease progression non-invasively. As the number of Parkinson’s patients increases globally, demand for these advanced diagnostic tools rises, thereby driving growth in the nuclear medicine (radiopharmaceuticals) market.
However, the increase in product development activities is further boosting the overall market of Nuclear medicine/ radiopharmeceuticals. For instance, in April 2024, Novartis’ radioligand therapy Lutathera® was approved by the FDA as the first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors.
Thus, all the above-mentioned factors are anticipated to propel the market for nuclear medicine (radiopharmaceuticals) in North America during the forecast period.
Europe Nuclear Medicine (Radiopharmaceuticals) Market Trends
The nuclear medicine (radiopharmaceuticals) market in Europe is growing due to the rising prevalence of cancer, cardiovascular diseases, and neurodegenerative disorders, increasing demand for early diagnosis, and the adoption of advanced imaging technologies like PET and SPECT for accurate, non-invasive disease detection and monitoring.
According to the Organisation for Economic Co-operation and Development, in 2022, cardiovascular diseases affected an estimated 62 million people in Europe. Accurate diagnosis and monitoring of heart conditions, including heart attacks, coronary artery disease, and arrhythmias, rely on advanced imaging techniques such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and myocardial perfusion scans. Radiopharmaceuticals play a crucial role in these procedures by enabling non-invasive assessment of blood flow, detection of damaged heart tissue, and evaluation of cardiac function, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.
Additionally, according to the International Agency for Research on Cancer, the estimated number of new Liver Cancer cases in Europe was 78,600 in 2025, and it is projected to reach 75,500 by 2045. The diagnosis, staging, and treatment of Thyroid Cancer heavily depend on nuclear imaging techniques such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography), along with radioisotope-based therapies like radioactive iodine. Radiopharmaceuticals are essential for detecting malignant thyroid tissue, monitoring metastasis, and delivering targeted therapy, allowing for precise and non-invasive disease management. This growing reliance on nuclear medicine is driving the expansion of the radiopharmaceuticals market.
However, the increase in product development activities is further boosting the overall market of nuclear medicine/ radiopharmaceuticals. For instance, in November 2024, Eckert & Ziegler Radiopharma GmbH received approval from the European Commission for its proprietary non-carrier-added Lutetium-177 chloride, Theralugand®.
Hence, all the factors mentioned above are expected to drive the market for nuclear medicine (radiopharmaceuticals) in Europe during the forecast period.
Asia-Pacific Nuclear Medicine (Radiopharmaceuticals) Market Trends
The nuclear medicine (radiopharmaceuticals) market in the Asia-Pacific region is expanding, driven by the increasing incidence of cancer, cardiovascular, and neurodegenerative disorders, rising healthcare spending, enhanced diagnostic infrastructure, and wider adoption of advanced imaging techniques and radiopharmaceutical treatments.
According to the International Agency for Research on Cancer, the estimated number of new thyroid cancer cases in Japan was 16,400 in 2025 and is projected to reach 15,100 by 2045. Thyroid cancer diagnosis and treatment rely on nuclear imaging techniques like PET and SPECT, along with radioisotope therapies such as radioactive iodine. Radiopharmaceuticals help detect malignant tissue, monitor metastasis, and deliver targeted therapy, driving growth in the nuclear medicine (radiopharmaceuticals) market.
Thus, the factors mentioned above are expected to boost the market of nuclear medicine (radiopharmaceuticals) across the Asia-Pacific region.
Who are the major players in the nuclear medicine (radiopharmaceuticals) market?
The following are the leading companies in the nuclear medicine (radiopharmaceuticals) market. These companies collectively hold the largest market share and dictate industry trends.
- Lantheus
- Cardinal Health
- GE Healthcare
- Curium Pharma
- Pharmalogic Holdings Corp.
- Novartis
- CambridgeIsotope Laboratories, Inc.
- Sotera health LLC
- Bracco Imaging SpA
- Jubilant Pharma Limited
- NECSA Ltd.
- IBA Radiopharma Solutions
- Bayer AG
- Norgine
- NorthStar Medical Radioisotopes, LLC
- Eckert & Ziegler
- Telix Pharmaceuticals Limited
- ITM Isotope Technologies Munich SE
- Mallinckrodt PLC
- ROTOP Pharmaka GmbH
- Others
The competitive landscape of the nuclear medicine (radiopharmaceuticals) market is shaped by the presence of several global and regional key players competing through product innovation, strategic collaborations, and geographic expansion. Leading companies such as GE Healthcare, Bayer AG, Novartis/Advanced Accelerator Applications, Jubilant Life Sciences, and Curium Pharma are heavily investing in research and development to introduce new radiopharmaceuticals for both diagnostic and therapeutic applications. Additionally, mergers, acquisitions, and partnerships are enabling companies to expand their product portfolios, enhance distribution networks, and access new markets, particularly in emerging regions. Moreover, regulatory approvals for novel radiotracers and continuous advancements in imaging technologies like PET, SPECT, and theranostics are driving innovation and competitive differentiation. Smaller specialized firms are also entering the market with niche radiopharmaceuticals, increasing market fragmentation and innovation.
Consequently, the competitive environment is fostering rapid technological advancements, expanded product offerings, and improved accessibility, which together are shaping the growth trajectory of the global nuclear medicine (radiopharmaceuticals) market.
Recent Developmental Activities in the Nuclear Medicine (Radiopharmaceuticals) Market
- In March 2025, Telix Pharmaceuticals Limited announced that the United States Food and Drug Administration (FDA) had approved its New Drug Application (NDA) for Gozellix® (TLX007‑CDx, a kit for the preparation of gallium‑68 [⁶⁸Ga] gozetotide injection), Telix’s next‑generation PSMA‑PET imaging agent for prostate cancer.
- Nuclear Medicine (Radiopharmaceuticals) by Product Type Exposure
- Single Photon Emission Computed Tomography (SPECT)
- Technetium-99m
- Iodine-125
- Xenon-133
- Others
- Positron Emission Tomography (PET)
- Fluorine-18
- Carbon-11
- Gallium-68
- Others
- Alpha Emitters
- Astatine-211
- Actinium-225
- Lead-212
- Others
- Beta Emitters
- Lutetium-177
- Iodine-131
- Yttrium-90
- Others
- Brachytherapy
- Nuclear Medicine (Radiopharmaceuticals) Application Exposure
Neurology
Oncology
Others
- Nuclear Medicine (Radiopharmaceuticals) End-Users Exposure
Diagnostic Centers
Others
- Nuclear Medicine (Radiopharmaceuticals) Geography Exposure
- United States Nuclear Medicine (Radiopharmaceuticals) Market
- Canada Nuclear Medicine (Radiopharmaceuticals) Market
- Mexico Nuclear Medicine (Radiopharmaceuticals) Market
- United Kingdom Nuclear Medicine (Radiopharmaceuticals) Market
- Germany Nuclear Medicine (Radiopharmaceuticals) Market
- France Nuclear Medicine (Radiopharmaceuticals) Market
- Italy Nuclear Medicine (Radiopharmaceuticals) Market
- Spain Nuclear Medicine (Radiopharmaceuticals) Market
- Rest of Europe Nuclear Medicine (Radiopharmaceuticals) Market
- China Nuclear Medicine (Radiopharmaceuticals) Market
- Japan Nuclear Medicine (Radiopharmaceuticals) Market
- India Nuclear Medicine (Radiopharmaceuticals) Market
- Australia Nuclear Medicine (Radiopharmaceuticals) Market
- South Korea Nuclear Medicine (Radiopharmaceuticals) Market
- Rest of Asia-Pacific Nuclear Medicine (Radiopharmaceuticals) Market
- South America Nuclear Medicine (Radiopharmaceuticals) Market
- Middle East Nuclear Medicine (Radiopharmaceuticals) Market
- Africa Nuclear Medicine (Radiopharmaceuticals) Market
AI-Powered Innovations and Applications:
The adoption of AI-powered innovations is significantly transforming the nuclear medicine (radiopharmaceuticals) market by enhancing both diagnostic accuracy and operational efficiency. AI algorithms are being integrated into imaging systems, such as PET and SPECT scanners, to improve image reconstruction, reduce noise, and detect abnormalities with higher precision, allowing clinicians to identify diseases at earlier stages. Additionally, AI facilitates automated workflow management, including patient scheduling, radiopharmaceutical dose calculation, and quality control, reducing human error and optimizing resource utilization. Moreover, AI applications in theranostics are enabling personalized treatment planning by analyzing large datasets to predict patient response to radiopharmaceutical therapies, such as targeted cancer treatments. The integration of AI also supports drug development, helping manufacturers design more effective radiotracers and accelerate regulatory approvals. Consequently, AI-driven innovations are improving clinical outcomes, reducing operational costs, and increasing the adoption of nuclear medicine procedures, thereby boosting the overall growth and efficiency of the nuclear medicine (radiopharmaceuticals) market.
U.S. Tariff Impact Analysis on Nuclear Medicine (Radiopharmaceuticals) Market:
The U.S. tariffs on imported medical equipment and radiopharmaceuticals have had a notable impact on the nuclear medicine (radiopharmaceuticals) market. Increased import duties on raw materials, isotopes, and diagnostic kits have raised the cost of production for domestic manufacturers relying on global supply chains. Additionally, higher costs are often passed on to healthcare providers, potentially limiting the adoption of advanced nuclear imaging and therapeutic procedures in cost-sensitive hospitals and clinics. Moreover, tariffs may prompt companies to invest in local manufacturing and supply chain diversification to reduce dependency on imports, which could increase initial capital expenditures but improve long-term market stability. Consequently, while tariffs may temporarily slow market growth due to higher prices, they also encourage strategic localization and innovation, shaping the competitive and operational landscape of the U.S. nuclear medicine (radiopharmaceuticals) market.
How This Analysis Helps Clients
- Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
- Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
- Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
- Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.
- Market size analysis for the current nuclear medicine (radiopharmaceuticals) market size (2025), and market forecast for 8 years (2026 to 2034)
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
- Key companies dominating the nuclear medicine (radiopharmaceuticals) market.
- Various opportunities available for the other competitors in the nuclear medicine (radiopharmaceuticals) market space.
- What are the top-performing segments in 2025? How these segments will perform in 2034?
- Which are the top-performing regions and countries in the current nuclear medicine (radiopharmaceuticals) market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for the nuclear medicine (radiopharmaceuticals) market growth in the future?
1. What is the growth rate of the nuclear medicine (radiopharmaceuticals) market?
- The nuclear medicine (radiopharmaceuticals) market is estimated to grow at a CAGR of 9.50% during the forecast period from 2026 to 2034.
- The global nuclear medicine (radiopharmaceuticals) market is expected to increase from USD 10,746.92 million in 2025 to USD 24,152.35 million by 2034, reflecting strong and sustained growth.
- North America is projected to lead the global nuclear medicine (radiopharmaceuticals) market due to the rising prevalence of cancer, cardiovascular, and chronic diseases, driven by lifestyle changes and high processed food consumption. Additionally, the presence of major domestic players, a growing geriatric population, and favorable reimbursement policies for radiopharmaceuticals in the U.S. are key factors supporting market growth in the region.
- The nuclear medicine (radiopharmaceuticals) market is witnessing strong growth due to the rising prevalence of cancer, cardiovascular, and chronic diseases, coupled with a growing geriatric population. Additionally, increasing demand for image-guided diagnostics and procedures, a robust pipeline of innovative products, and supportive government initiatives are driving adoption. Moreover, ongoing R&D activities, regulatory approvals, new product launches, and the presence of key industry players are further fueling market expansion, positioning nuclear medicine as a critical component of modern healthcare.
- Some of the key market players operating in the nuclear medicine (radiopharmaceuticals) market include Lantheus, Cardinal Health, GE Healthcare, Curium Pharma, Pharmalogic Holdings Corp., Novartis, Cambridge Isotope Laboatories, Inc., Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, NECSA Ltd., IBA Radiopharma Solutions, Bayer AG, Norgine, NorthStar Medical Radioisotopes, LLC, Eckert & Ziegler, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, ROTOP Pharmaka GmbH and others.
Table of Contents
150 Pages
- 1. Nuclear Medicine (Radiopharmaceuticals) Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumption
- 2. Nuclear Medicine (Radiopharmaceuticals) Market Executive Summary
- 2.1 Market at Glance
- 3. Nuclear Medicine (Radiopharmaceuticals) Market Key Factors Analysis
- 3.1 Nuclear Medicine (Radiopharmaceuticals) Market Drivers
- 3.1.1 Rising prevalence of cancer, cardiovascular, and other chronic diseases
- 3.1.2 Increasing demand for targeted radiotherapy
- 3.1.3 Growing adoption of PET and SPECT imaging
- 3.2 Nuclear Medicine (Radiopharmaceuticals) Market Restraints and Challenges
- 3.2.1 Short half-life, radiation exposure concerns, and high infrastructure and operational cost
- 3.2.2 Stringent regulatory approval process
- 3.3 Nuclear Medicine (Radiopharmaceuticals) Market Opportunity
- 3.3.1 Rising research and development opportunities and presence of robust products in pipeline
- 4. Impact Analysis
- 4.1 AI-Powered Innovations and Applications
- 4.2 U.S. Tariff Impact Analysis
- 5. Regulatory Analysis
- 5.1 The United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
- 6. Nuclear Medicine (Radiopharmaceuticals) Market Porter’s Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Consumers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
- 7. Nuclear Medicine (Radiopharmaceuticals) Market Assessment
- 7.1 By Product Type
- 7.1.1 Diagnostic Products
- 7.1.1.1 Single Photon Emission Computed Tomography (SPECT)
- 7.1.1.1.1 Technetium-99m
- 7.1.1.1.2 Iodine-125
- 7.1.1.1.3 Xenon-133
- 7.1.1.1.4 Others
- 7.1.1.2 Positron Emission Tomography (PET)
- 7.1.1.2.1 Fluorine-18
- 7.1.1.2.2 Carbon-11
- 7.1.1.2.3 Gallium-68
- 7.1.1.2.4 Others
- 7.1.2 Therapeutics Products
- 7.1.2.1 Alpha Emitters
- 7.1.2.1.1 Astatine-211
- 7.1.2.1.2 Actinium-225
- 7.1.2.1.3 Lead-212
- 7.1.2.1.4 Others
- 7.1.2.2 Beta Emitters
- 7.1.2.2.1 Lutetium-177
- 7.1.2.2.2 Iodine-131
- 7.1.2.2.3 Yttrium-90
- 7.1.2.2.4 Others
- 7.1.2.3 Brachytherapy
- 7.2 By Application
- 7.2.1 Cardiology
- 7.2.2 Neurology
- 7.2.3 Oncology
- 7.2.4 Others
- 7.3 By End-Users
- 7.3.1 Hospitals
- 7.3.2 Diagnostic Centers
- 7.3.3 Others
- 7.4 By Geography
- 7.4.1 North America
- 7.4.1.1 United States Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.1.2 Canada Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.1.3 Mexico Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.2 Europe
- 7.4.2.1 France Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.2.2 Germany Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.2.3 United Kingdom Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.2.4 Italy Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.2.5 Spain Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.2.6 Rest of Europe Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.3 Asia-Pacific
- 7.4.3.1 China Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.3.2 Japan Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.3.3 India Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.3.4 Australia Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.3.5 South Korea Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.3.6 Rest of Asia-Pacific Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.4 Rest of the World (RoW)
- 7.4.4.1 Middle East Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.4.2 Africa Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
- 7.4.4.3 South America Nuclear Medicine (Radiopharmaceuticals) Market Size In USD Million (2023-2034)
- 8. Competitive Landscape
- 9. Nuclear Medicine (Radiopharmaceuticals) Market Company and Product Profiles
- 9.1 Lantheus
- 9.1.1 Company Overview
- 9.1.2 Company Snapshot
- 9.1.3 Financial Overview
- 9.1.4 Product Listing
- 9.1.5 Entropy
- 9.2 Cardinal Health
- 9.2.1 Company Overview
- 9.2.2 Company Snapshot
- 9.2.3 Financial Overview
- 9.2.4 Product Listing
- 9.2.5 Entropy
- 9.3 GE Healthcare
- 9.3.1 Company Overview
- 9.3.2 Company Snapshot
- 9.3.3 Financial Overview
- 9.3.4 Product Listing
- 9.3.5 Entropy
- 9.4 Curium Pharma
- 9.4.1 Company Overview
- 9.4.2 Company Snapshot
- 9.4.3 Financial Overview
- 9.4.4 Product Listing
- 9.4.5 Entropy
- 9.5 Pharmalogic Holdings Corp.
- 9.5.1 Company Overview
- 9.5.2 Company Snapshot
- 9.5.3 Financial Overview
- 9.5.4 Product Listing
- 9.5.5 Entropy
- 9.6 Novartis
- 9.6.1 Company Overview
- 9.6.2 Company Snapshot
- 9.6.3 Financial Overview
- 9.6.4 Product Listing
- 9.6.5 Entropy
- 9.7 Cambridge Isotope Laboratories
- 9.7.1 Company Overview
- 9.7.2 Company Snapshot
- 9.7.3 Financial Overview
- 9.7.4 Product Listing
- 9.7.5 Entropy
- 9.8 Sotera Health
- 9.8.1 Company Overview
- 9.8.2 Company Snapshot
- 9.8.3 Financial Overview
- 9.8.4 Product Listing
- 9.8.5 Entropy
- 9.9 Bracco Imaging SpA
- 9.9.1 Company Overview
- 9.9.2 Company Snapshot
- 9.9.3 Financial Overview
- 9.9.4 Product Listing
- 9.9.5 Entropy
- 9.10 Jubilant Pharma Ltd.
- 9.10.1 Company Overview
- 9.10.2 Company Snapshot
- 9.10.3 Financial Overview
- 9.10.4 Product Listing
- 9.10.5 Entropy
- 9.11 NECSA Ltd.
- 9.11.1 Company Overview
- 9.11.2 Company Snapshot
- 9.11.3 Financial Overview
- 9.11.4 Product Listing
- 9.11.5 Entropy
- 9.12 IBA Radiopharma Solutions
- 9.12.1 Company Overview
- 9.12.2 Company Snapshot
- 9.12.3 Financial Overview
- 9.12.4 Product Listing
- 9.12.5 Entropy
- 9.13 Bayer AG
- 9.13.1 Company Overview
- 9.13.2 Company Snapshot
- 9.13.3 Financial Overview
- 9.13.4 Product Listing
- 9.13.5 Entropy
- 9.14 Norgine
- 9.14.1 Company Overview
- 9.14.2 Company Snapshot
- 9.14.3 Financial Overview
- 9.14.4 Product Listing
- 9.14.5 Entropy
- 9.15 NorthStar Medical Radioisotopes, LLC
- 9.15.1 Company Overview
- 9.15.2 Company Snapshot
- 9.15.3 Financial Overview
- 9.15.4 Product Listing
- 9.15.5 Entropy
- 9.16 Eckert & Ziegler
- 9.16.1 Company Overview
- 9.16.2 Company Snapshot
- 9.16.3 Financial Overview
- 9.16.4 Product Listing
- 9.16.5 Entropy
- 9.17 Telix Pharmaceuticals
- 9.17.1 Company Overview
- 9.17.2 Company Snapshot
- 9.17.3 Financial Overview
- 9.17.4 Product Listing
- 9.17.5 Entropy
- 9.18 ITM Isotope Technologies Munich SE
- 9.18.1 Company Overview
- 9.18.2 Company Snapshot
- 9.18.3 Financial Overview
- 9.18.4 Product Listing
- 9.18.5 Entropy
- 9.19 Mallinckrodt PLC
- 9.19.1 Company Overview
- 9.19.2 Company Snapshot
- 9.19.3 Financial Overview
- 9.19.4 Product Listing
- 9.19.5 Entropy
- 9.20 ROTOP Pharmaka GmbH
- 9.20.1 Company Overview
- 9.20.2 Company Snapshot
- 9.20.3 Financial Overview
- 9.20.4 Product Listing
- 9.20.5 Entropy
- 10. KOL Views
- 11. Project Approach
- 12. About DelveInsight
- 13. Disclaimer & Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.